COLD + SINUS CAPLETS TABLET

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

Disponible desde:

VITA HEALTH PRODUCTS INC

Código ATC:

M01AE51

Designación común internacional (DCI):

IBUPROFEN, COMBINATIONS

Dosis:

200MG; 30MG

formulario farmacéutico:

TABLET

Composición:

IBUPROFEN 200MG; PSEUDOEPHEDRINE HYDROCHLORIDE 30MG

Vía de administración:

ORAL

Unidades en paquete:

10/20

tipo de receta:

OTC

Área terapéutica:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Resumen del producto:

Active ingredient group (AIG) number: 0222394001; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2006-10-17

Ficha técnica

_ _
_Page 1 of 50_
PRODUCT MONOGRAPH
COLD + SINUS CAPLETS
Ibuprofen and Pseudoephedrine Hydrochloride Tablets USP
Ibuprofen 200 mg, Pseudoephedrine Hydrochloride 30 mg
USP
Analgesic/Antipyretic/Nasal Decongestant
Vita Health Products Inc.
150 Beghin Avenue
Winnipeg, Manitoba
Canada, R2J 3W2
Control No. 151199
Date of Revision:
January 30, 2012
_ _
_ _
_Page 2 of 50_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
ADVERSE
REACTIONS..................................................................................................11
DRUG INTERACTIONS
..................................................................................................17
DOSAGE AND
ADMINISTRATION..............................................................................20
OVERDOSAGE
...............................................................................................................21
ACTION AND CLINICAL PHARMACOLOGY
............................................................23
STORAGE AND
STABILITY..........................................................................................28
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................28
PART II: SCIENTIFIC INFORMATION
...............................................................................29
PHARMACEUTICAL
INFORMATION..........................................................................29
CLINICAL
TRIALS..........................................................................................................31
DETAILED
PHARMACOLOGY.....................................................................................33
TOXICOLOGY
.......